Enliven Therapeutics Overview
Enliven Therapeutics (ELVN) has a P/E ratio of -33.12, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-33.12
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Enliven Therapeutics (ELVN) currently reports a P/E ratio of -33.12. That is below the Healthcare sector average of 24.78. Use the charts on this page to explore Enliven Therapeutics's P/E ratio history and peer comparisons.
Enliven Therapeutics's P/E ratio of -33.12 is lower than the Healthcare sector average of 24.78. That is roughly 233.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Enliven Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -33.12, ELVN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -33.12, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for Enliven Therapeutics, and consider following ELVN for alerts when major investors trade the stock.
Enliven Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -33.12 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELVN with unrelated industries.
